Therapeutics News and Research

RSS

Arana and Greenovation in anti-cancer co-development deal

Arana Therapeutics Limited and Germany-based greenovation Biotech GmbH have entered into a collaborative agreement to develop next generation anti-cancer antibodies.

2 Jun 2008

Celldex Therapeutics vaccine may double survival in patients with deadly brain tumors

A vaccine aimed at inducing immunity to the most common and deadly type of brain tumor may stave off recurrence and more than double survival in patients, according to a new study led by researchers in Duke's Preston Robert Tisch Brain Tumor Center.

2 Jun 2008

U.S. Patent Office confirms second of four Viread patents

Gilead Sciences, Inc. has announced that the U.S. Patent & Trademark Office (PTO) has completed the second of four reexamination proceedings and has confirmed the patentability of U.S. Patent No. 5,922,695, which covers the composition of matter for Viread (tenofovir disoproxil fumarate). On May 20, Gilead announced that the U.S. PTO confirmed the patentability of U.S. Patent No. 6,043,230.

2 Jun 2008

New cancer stem cell identified behind metastatic tumors

The molecular profile of cancer stem cells that initiate metastatic colon tumors is significantly different from those responsible for primary tumors, according to new research from a team at Weill Cornell Medical College.

28 May 2008

First patient enrolled in phase III study of Bevacizumab and Trastuzumab in early breast cancer

A new international study for women with HER2-positive breast cancer is open for enrollment. The pivotal BETH (BEvacizumab and Trastuzumab Adjuvant Therapy in HER2-positive Breast Cancer) study is a Phase III clinical research trial that is investigating the benefits of combining two monoclonal antibodies, the anti-angiogenic, bevacizumab (Avastin) and the targeted therapy trastuzumab (Herceptin), together with chemotherapy for the treatment of patients with early stage HER2-positive breast cancer.

27 May 2008

Boost for cancer research in Leicestershire

A new approach to pain relief, investigation of a gene that triggers colorectal cancer and the prevention, early diagnosis and treatment of ovarian cancer are three research projects at the University of Leicester, which are to benefit from funding from the Leicestershire and Rutland charity Hope Against Cancer.

21 May 2008

Oncolytics Biotech announces issuance of 27th U.S. patent

Oncolytics Biotech Inc. today announced that it has been granted U.S. Patent 7,374,752 entitled "Reovirus for the Treatment of Cellular Proliferative Disorders."

20 May 2008

Mapping of prostate cancer genes opens the door to new treatments

Genetic changes during the initiation and progression of prostate cancer have eluded scientists to date. Now for the first time researchers have identified a specific gene expression profile of prostate cancer stem cells, with important implications for future treatments.

19 May 2008

Erection problems may signal serious heart disease

Erectile dysfunction is always a matter of the heart, but new research shows that more than romance is at stake. Two new studies of men with type 2 diabetes found that erectile dysfunction (ED) was a powerful early warning sign for serious heart disease, including heart attack and death.

19 May 2008

U.S. patent office grants re-examination of RNA splicing microarray patent on behalf of Jivan

Jivan Biologics, Inc. announced today that the United States Patent and Trademark Office has ordered the re-examination of U.S. Patent No. 6,881,571. The serial number for the reexamination is 90/009,017.

19 May 2008

Biopure Corporation wins European patent challenge

Biopure Corporation announced today that it has successfully defended a challenge at the European Patent Office (EPO) to its European Patent entitled, "A Method for Chromatographic Removal of Prions."

19 May 2008

Cancer Research UK and AstraZeneca announce innovative deal for promising anti-cancer compound

Cancer Research UK and Cancer Research Technology (CRT) - the charity's development and commercialisation arm - today announced an innovative new arrangement to progress into clinical development a potential anti-cancer compound from AstraZeneca.

19 May 2008

Personalized therapy for asthma and chronic obstructive pulmonary disease could soon be here

Researchers at Washington University School of Medicine in St. Louis have defined a new type of immune response that is activated in patients with severe asthma and COPD (chronic obstructive pulmonary disease). Their discovery could dramatically improve diagnosis and treatment of patients with chronic inflammatory lung disease.

19 May 2008

Pfizer and Peter MacCallum support the future of cancer research in Australia

Australia's reputation for excellence in cancer research has been strengthened with the launch of the Peter MacCallum Pfizer Translational Oncology Research Collaborative Hub (TORCH) at the Peter MacCallum Cancer Centre, by the Minister for Innovation, Industry, Science and Research, Senator the Hon. Kim Carr.

18 May 2008

New hay fever jab promises year long relief for sufferers

Relief is in sight for millions of hay fever sufferers with the promise of a jab, which lasts for a year, that significantly reduces symptoms.

15 May 2008

Arsenic-based agent shown to help eradicate leukemia-initiating cells

In both leukemia and solid tumors, there exists among the multitude of warrior cancer cells a small subgroup that work undercover, patiently lying in wait to launch their attacks. Known as either cancer initiating cells (CICs) or leukemia initiating cells (LICs), these stealth populations are impervious to conventional chemotherapy and undaunted by targeted cancer therapies. When a leukemia patient relapses following a period of remission, it is the LICs that bear responsibility for the disease's reemergence.

12 May 2008

Cytopia announces novel anti-cancer drug development collaboration

Cytopia Limited today announced that it has entered into an anti-cancer drug discovery and development collaboration with Cancer Therapeutics CRC Pty Ltd. This agreement leverages Cytopia's early stage drug discovery pipeline of kinase inhibitors, a class of targeted therapeutics that is one of the fastest growing segments of the cancer drug market.

9 May 2008

Platypus venom linked to pain relief

New research released today in the scientific research journal Nature reveals links between platypus venom and its potential benefits for advancing pain relief and antibiotic medication

7 May 2008

Suicide victims who were abused have genetic brain difference

Canadian researchers have found that childhood abuse victims who later commit suicide have marked genetic differences in their brains.

7 May 2008

New understanding of how a mole develops into melanoma

Researchers have discovered how a mole develops into melanoma by showing the interaction of two key proteins involved in 60-70 percent of tumors. The Penn State scientists also demonstrate that therapeutic targeting of these proteins is necessary for drugs to effectively treat this deadly form of cancer.

6 May 2008